Asano et al.45
|
RA |
Cyclosporine |
4/8 (50%) |
PNH did not correlate to response |
Atoyebi et al.31
|
RA, RARS |
Cyclosporine |
0/6 (0%) |
Drug withdrawn in 3 patients due to adverse side-effects |
Catalano et al.29
|
RA |
Cyclosporine |
5/9 (56%) |
All patients had hypocellular marrows |
Chen et al.27
|
RA, RARS, RAEB |
Cyclosporine |
20/32(62.5%) |
Survival time longer in responders |
Dixit et al.46
|
RA, RAEB, RARS |
Cyclosporine |
13/19 (68%) |
RA patients had higher response |
Ishikawa et al.28
|
RA, RAEB, RARS |
Cyclosporine |
10/19 (53%) |
HI seen within 24 weeks |
Okamoto et al.30
|
RA, RAEB |
Cyclosporine |
6/10 (60%) |
HLA-DR15 favorable predictive factor |
Selleri et al.47
|
Hypocellular MDS |
Cyclosporine |
8/11(73%) |
All patients were hypocellular |
Killick et al.32
|
RA, RAEB, RARS |
Horse ATG |
10/20 (50%) |
8/13 RA patients responded |
Molldrem et al.22
|
RA, RAEB, RARS |
Horse ATG |
11/25 (44%) |
9/14 RA patients responded |
Steensma et al.33
|
RA, RAEB-1 |
Horse ATG |
0/8 (0%) |
Study stopped early due to lack of efficacy, 6 RAEB-1 patients |
Passweg et al.35
|
RA, RARS, RAEB-1, RAEB-2, hypocellular |
Horse ATG + cyclosporine |
13/45(29%) |
Trial compared to best supportive care |
Yazji et al.48
|
RA, RARS, RAEB-t, CMML |
Horse ATG + cyclosporine |
5/31 (16%) |
3/18 RA/RARS patients achieved durable CR |
Scott et al.21
|
RA, RARS, RCMD, RCMD-RS, RAEB-1 |
Horse ATG + etanercept |
14/25(56%) |
All responders responded by 8 weeks |
Stadler et al.34
|
RA, RAEB, CMML |
Horse ATG vs. Rabbit ATG |
12/35 (34%) |
Horse or Rabbit ATG efficacious in RA patients with short duration of disease |
Broliden et al.36
|
RA, RAEB |
Rabbit ATG + cyclosporine |
6/20 (30%) |
Poorly tolerated in patients older than 70 |
Sloand et al.37
|
Low-risk, Intermediate-1, Intermediate-2 |
Alemtuzumab |
17/22 (77%) Int-1 4/7 (57%) Int-2 |
Patients selected based on likely to respond criteria |
Platzbecker et al.40
|
RA, RARS, RCMD, RCMD-RS, RAEB-1, RAEB-2 |
Sirolimus |
3/19 (16%) |
2 responders were RAEB-1 and RAEB-2 |